SG10201702157QA - Activin-actrii antagonists and uses for increasing red blood cell levels - Google Patents
Activin-actrii antagonists and uses for increasing red blood cell levelsInfo
- Publication number
- SG10201702157QA SG10201702157QA SG10201702157QA SG10201702157QA SG10201702157QA SG 10201702157Q A SG10201702157Q A SG 10201702157QA SG 10201702157Q A SG10201702157Q A SG 10201702157QA SG 10201702157Q A SG10201702157Q A SG 10201702157QA SG 10201702157Q A SG10201702157Q A SG 10201702157QA
- Authority
- SG
- Singapore
- Prior art keywords
- activin
- red blood
- blood cell
- cell levels
- actrii antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 210000003743 erythrocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87568206P | 2006-12-18 | 2006-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201702157QA true SG10201702157QA (en) | 2017-04-27 |
Family
ID=39183159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201702157QA SG10201702157QA (en) | 2006-12-18 | 2007-12-18 | Activin-actrii antagonists and uses for increasing red blood cell levels |
Country Status (29)
Country | Link |
---|---|
US (7) | US7988973B2 (es) |
EP (6) | EP2446896A1 (es) |
JP (8) | JP5415279B2 (es) |
KR (6) | KR102223231B1 (es) |
CN (4) | CN105582521A (es) |
AU (1) | AU2007334333B2 (es) |
BR (1) | BRPI0720476B1 (es) |
CA (1) | CA2672758C (es) |
CO (1) | CO6230995A2 (es) |
CR (1) | CR10889A (es) |
DK (2) | DK2124999T3 (es) |
EA (3) | EA035911B1 (es) |
EC (1) | ECSP099514A (es) |
ES (1) | ES2396734T3 (es) |
HK (3) | HK1137368A1 (es) |
HR (1) | HRP20121035T1 (es) |
IL (5) | IL199451A (es) |
ME (1) | ME02335B (es) |
MX (1) | MX2009006651A (es) |
MY (3) | MY162136A (es) |
NZ (4) | NZ707292A (es) |
PL (2) | PL2124999T3 (es) |
PT (1) | PT2124999E (es) |
RS (1) | RS52537B (es) |
SG (1) | SG10201702157QA (es) |
SI (1) | SI2124999T1 (es) |
UA (2) | UA101309C2 (es) |
WO (1) | WO2008076437A2 (es) |
ZA (2) | ZA200904454B (es) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
JP2008507288A (ja) * | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ActRII受容体ポリペプチド、方法、および組成物 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
NZ568369A (en) | 2005-11-23 | 2011-10-28 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for promoting bone growth |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
KR102223231B1 (ko) * | 2006-12-18 | 2021-03-08 | 악셀레론 파마 인코포레이티드 | 액티빈-actrii 길항물질과 적혈구 수준을 증가시키기 위한 이의 용도 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
WO2008094708A2 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
TWI454479B (zh) | 2007-03-06 | 2014-10-01 | Amgen Inc | 變異之活動素受體多肽及其用途 |
US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
EP2207562B1 (en) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
WO2009158025A2 (en) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
KR20190049912A (ko) * | 2008-06-26 | 2019-05-09 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
LT2340031T (lt) * | 2008-08-14 | 2019-08-12 | Acceleron Pharma Inc. | Gdf gaudyklės, skirtos naudoti anemijos gydymui |
AU2015202035B2 (en) * | 2008-08-14 | 2017-03-23 | Acceleron Pharma Inc. | Use of GDF traps to increase red blood cell levels |
US20110262466A1 (en) * | 2008-10-16 | 2011-10-27 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
PE20150680A1 (es) | 2008-11-26 | 2015-05-16 | Amgen Inc | Variantes de polipeptidos receptores de activina iib y aplicaciones de estos |
CA2749544A1 (en) * | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
BR122021017187B1 (pt) * | 2009-06-12 | 2022-07-12 | Acceleron Pharma Inc | Ácido nucléico e polipeptídeo recombinante, preparação farmacêutica compreendendo o dito polipeptídeo e usos terapêuticos da mesma |
KR101882521B1 (ko) * | 2009-08-13 | 2018-07-27 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
KR20210029836A (ko) * | 2009-09-09 | 2021-03-16 | 악셀레론 파마 인코포레이티드 | ActRIIb 길항제들와 이의 투약 및 용도 |
US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
JP5836961B2 (ja) * | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ, インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
JP6214537B2 (ja) * | 2012-08-21 | 2017-10-25 | 国立大学法人九州大学 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
AU2013334660B2 (en) * | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
ES2884095T3 (es) * | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
EP2951205B1 (en) | 2013-02-01 | 2021-08-11 | Santa Maria Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
MA51074A (fr) | 2014-06-04 | 2020-10-14 | Acceleron Pharma Inc | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
CN107135646B (zh) * | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
AU2015339134B2 (en) | 2014-10-30 | 2021-06-17 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
KR102556991B1 (ko) | 2014-12-03 | 2023-07-19 | 셀진 코포레이션 | 액티빈-ActRII 길항제 및 빈혈 치료를 위한 용도 |
EP3250588A1 (en) * | 2015-01-29 | 2017-12-06 | Board of Trustees of Michigan State University | Cryptic polypeptides and uses thereof |
US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
KR20170129233A (ko) | 2015-03-26 | 2017-11-24 | 악셀레론 파마 인코포레이티드 | 폴리스타틴-관련된 융합 단백질 및 이들의 용도 |
EA202190016A1 (ru) * | 2015-04-06 | 2021-08-31 | Акселерон Фарма Инк. | Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета |
JP6959487B2 (ja) | 2015-04-22 | 2021-11-02 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 筋消耗疾患治療用の新規なハイブリッドactriibリガンド捕集タンパク質 |
IL284686B2 (en) * | 2015-05-13 | 2023-05-01 | Celgene Corp | Treatment of beta-thalassemia using actrii ligand traps |
EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
KR102605758B1 (ko) * | 2015-07-06 | 2023-11-23 | 미츠비시 가스 가가쿠 가부시키가이샤 | 수지 조성물, 프리프레그, 레진 시트, 적층판, 및 프린트 배선판 |
US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
WO2017177013A1 (en) * | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
RU2021114098A (ru) | 2016-07-15 | 2021-12-14 | Акселерон Фарма Инк. | Композиции и способы для лечения легочной гипертензии |
JP6944768B2 (ja) | 2016-08-29 | 2021-10-06 | エア・ウォーター株式会社 | ペリクルの製造方法 |
US11267865B2 (en) | 2016-10-05 | 2022-03-08 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
CN110461349A (zh) | 2016-11-10 | 2019-11-15 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
KR20240014600A (ko) | 2017-03-24 | 2024-02-01 | 노바르티스 아게 | 심장질환 예방 및 치료 방법 |
CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
CN112601538A (zh) * | 2018-05-09 | 2021-04-02 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
BR112022010424A2 (pt) | 2019-11-29 | 2022-08-23 | Kymab Ltd | Tratamento para sobrecarga de ferro fisiológica |
US20230057399A1 (en) * | 2021-08-16 | 2023-02-23 | Thermolife International, Llc | Iron supplement compositions and methods of use thereof |
WO2023141724A1 (en) | 2022-01-28 | 2023-08-03 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US71927A (en) * | 1867-12-10 | Improvement in apparatus fob turning on gas | ||
JPH0637520B2 (ja) * | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
US4973577A (en) * | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
WO1992004913A1 (en) * | 1990-09-13 | 1992-04-02 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
EP0542971A1 (en) | 1991-05-10 | 1993-05-26 | The Salk Institute For Biological Studies | CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-$g(b) SUPERFAMILY |
US6692925B1 (en) * | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5831050A (en) * | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
DE69434934D1 (de) | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5658876A (en) * | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
EP0771873A3 (en) * | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
US6953662B2 (en) * | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
WO2000043781A2 (en) | 1999-01-21 | 2000-07-27 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
WO2000062809A1 (fr) | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes |
US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
WO2001043763A1 (en) * | 1999-12-15 | 2001-06-21 | Research Development Foundation | Betaglycan as an inhibin receptor and uses thereof |
JP4487376B2 (ja) * | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
WO2002043759A2 (en) | 2000-12-01 | 2002-06-06 | Wyeth | Method and composition for modulating bone growth |
TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
EP1390497A2 (en) * | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
US6855344B2 (en) * | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
US7192717B2 (en) * | 2002-02-21 | 2007-03-20 | Wyeth | GASP1: a follistatin domain containing protein |
US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
JP2004121008A (ja) * | 2002-09-30 | 2004-04-22 | Toray Ind Inc | ネコアクチビンaおよびそのサブユニット並びにその製造法 |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
WO2004086953A2 (en) * | 2003-03-26 | 2004-10-14 | The Board Of Trustees Of The University Of Arkansas | Method for diagnosis and treatment of bone turnover |
WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
WO2005009460A2 (en) * | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
JP2007530055A (ja) | 2004-03-26 | 2007-11-01 | アクセルロン ファーマ インコーポレーテッド | Bmp−3プロペプチドおよび関連する方法 |
AU2005230854A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc | BMP-7 variants with improved properties |
US7465706B2 (en) | 2004-06-24 | 2008-12-16 | Acceleron Pharma Inc. | GDF3 propeptides and related methods |
JP2008507288A (ja) * | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ActRII受容体ポリペプチド、方法、および組成物 |
CA2581896C (en) | 2004-09-29 | 2015-11-10 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
EP2335719B1 (en) | 2005-02-16 | 2015-06-24 | The General Hospital Corporation | Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism |
EP1884235A1 (en) * | 2005-04-26 | 2008-02-06 | Ajinomoto Co., Inc. | Myeloerythroid progenitor differentiation inducer |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
NZ568369A (en) * | 2005-11-23 | 2011-10-28 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for promoting bone growth |
JP2009518422A (ja) | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
US7361510B2 (en) * | 2006-01-20 | 2008-04-22 | Beckman Coulter, Inc. | Methods of detection of iron deficiency |
BRPI0713096A2 (pt) * | 2006-05-09 | 2012-10-16 | Hemaquest Pharmaceuticals Inc | métodos para tratar distúrbios sangüìneos |
CN101522021B (zh) * | 2006-07-21 | 2014-07-30 | 莱因实验室 | 醋酸钙的液体组合物 |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
KR102223231B1 (ko) * | 2006-12-18 | 2021-03-08 | 악셀레론 파마 인코포레이티드 | 액티빈-actrii 길항물질과 적혈구 수준을 증가시키기 위한 이의 용도 |
WO2008094708A2 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
TWI454479B (zh) | 2007-03-06 | 2014-10-01 | Amgen Inc | 變異之活動素受體多肽及其用途 |
EP2150560A1 (en) * | 2007-06-01 | 2010-02-10 | Wyeth | Methods and compositions for modulating bmp-10 activity |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
MX2009012558A (es) | 2007-08-03 | 2010-04-21 | Biomarin Iga Ltd | Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne. |
EP2207562B1 (en) * | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20110104133A1 (en) | 2008-05-06 | 2011-05-05 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
-
2007
- 2007-12-18 KR KR1020207006948A patent/KR102223231B1/ko active IP Right Grant
- 2007-12-18 ES ES07863068T patent/ES2396734T3/es active Active
- 2007-12-18 DK DK07863068.8T patent/DK2124999T3/da active
- 2007-12-18 EP EP11195282A patent/EP2446896A1/en not_active Withdrawn
- 2007-12-18 BR BRPI0720476-0A patent/BRPI0720476B1/pt active IP Right Grant
- 2007-12-18 KR KR1020187004410A patent/KR20180019768A/ko active Search and Examination
- 2007-12-18 NZ NZ707292A patent/NZ707292A/en unknown
- 2007-12-18 CN CN201610145040.4A patent/CN105582521A/zh active Pending
- 2007-12-18 ME MEP-2016-200A patent/ME02335B/me unknown
- 2007-12-18 DK DK11195130.7T patent/DK2468290T3/en active
- 2007-12-18 RS RS20120548A patent/RS52537B/en unknown
- 2007-12-18 EA EA201201199A patent/EA035911B1/ru not_active IP Right Cessation
- 2007-12-18 WO PCT/US2007/025868 patent/WO2008076437A2/en active Application Filing
- 2007-12-18 KR KR1020167001731A patent/KR101831534B1/ko active IP Right Grant
- 2007-12-18 UA UAA200906746A patent/UA101309C2/ru unknown
- 2007-12-18 KR KR1020097014226A patent/KR101688228B1/ko active IP Right Grant
- 2007-12-18 KR KR1020217005960A patent/KR20210027508A/ko not_active Application Discontinuation
- 2007-12-18 CN CN201610144786.3A patent/CN105797135A/zh active Pending
- 2007-12-18 CA CA2672758A patent/CA2672758C/en active Active
- 2007-12-18 EP EP21205033.0A patent/EP4026553A1/en not_active Withdrawn
- 2007-12-18 PL PL07863068T patent/PL2124999T3/pl unknown
- 2007-12-18 EP EP11195130.7A patent/EP2468290B1/en active Active
- 2007-12-18 SG SG10201702157QA patent/SG10201702157QA/en unknown
- 2007-12-18 PT PT78630688T patent/PT2124999E/pt unknown
- 2007-12-18 MY MYPI20092540A patent/MY162136A/en unknown
- 2007-12-18 MY MYPI2016001928A patent/MY188973A/en unknown
- 2007-12-18 SI SI200731110T patent/SI2124999T1/sl unknown
- 2007-12-18 MY MYPI2013002844A patent/MY170509A/en unknown
- 2007-12-18 MX MX2009006651A patent/MX2009006651A/es active IP Right Grant
- 2007-12-18 PL PL11195130T patent/PL2468290T3/pl unknown
- 2007-12-18 JP JP2009542880A patent/JP5415279B2/ja active Active
- 2007-12-18 EP EP17182870.0A patent/EP3320911B1/en active Active
- 2007-12-18 CN CN201410670950.5A patent/CN104524548A/zh active Pending
- 2007-12-18 EA EA202091230A patent/EA202091230A3/ru unknown
- 2007-12-18 NZ NZ720955A patent/NZ720955A/en unknown
- 2007-12-18 EP EP07863068A patent/EP2124999B1/en active Active
- 2007-12-18 US US12/002,872 patent/US7988973B2/en active Active
- 2007-12-18 AU AU2007334333A patent/AU2007334333B2/en active Active
- 2007-12-18 EA EA200970603A patent/EA018037B1/ru unknown
- 2007-12-18 NZ NZ577847A patent/NZ577847A/en unknown
- 2007-12-18 EP EP11195140.6A patent/EP2468291B1/en active Active
- 2007-12-18 KR KR1020157013795A patent/KR101803620B1/ko active IP Right Grant
- 2007-12-18 NZ NZ617196A patent/NZ617196A/en unknown
- 2007-12-18 UA UAA201214689A patent/UA116871C2/uk unknown
- 2007-12-19 CN CN200780051416.4A patent/CN101687015B/zh active Active
-
2008
- 2008-09-29 US US12/286,381 patent/US20100204092A1/en not_active Abandoned
- 2008-09-29 US US12/286,333 patent/US8007809B2/en active Active
-
2009
- 2009-06-18 IL IL199451A patent/IL199451A/en active IP Right Grant
- 2009-06-24 CR CR10889A patent/CR10889A/es unknown
- 2009-06-25 ZA ZA2009/04454A patent/ZA200904454B/en unknown
- 2009-07-09 CO CO09071017A patent/CO6230995A2/es not_active Application Discontinuation
- 2009-07-14 EC EC2009009514A patent/ECSP099514A/es unknown
-
2010
- 2010-06-01 HK HK10105399.4A patent/HK1137368A1/xx unknown
-
2011
- 2011-07-22 US US13/189,353 patent/US20120052067A1/en not_active Abandoned
-
2012
- 2012-03-19 ZA ZA2012/02027A patent/ZA201202027B/en unknown
- 2012-12-14 HR HRP20121035TT patent/HRP20121035T1/hr unknown
-
2013
- 2013-03-18 JP JP2013055102A patent/JP5865281B2/ja active Active
- 2013-11-26 JP JP2013243668A patent/JP2014040483A/ja active Pending
-
2015
- 2015-08-12 IL IL240523A patent/IL240523A/en active IP Right Grant
- 2015-08-12 IL IL240524A patent/IL240524A/en active IP Right Grant
- 2015-10-22 HK HK15110382.8A patent/HK1209624A1/xx unknown
- 2015-10-27 JP JP2015211115A patent/JP2016020391A/ja active Pending
-
2017
- 2017-02-03 JP JP2017018409A patent/JP2017075187A/ja active Pending
- 2017-06-19 JP JP2017119494A patent/JP2017155064A/ja not_active Withdrawn
- 2017-12-11 IL IL256247A patent/IL256247B/en unknown
-
2018
- 2018-10-31 HK HK18113934.2A patent/HK1254840A1/zh unknown
-
2019
- 2019-01-04 US US16/240,276 patent/US20200031903A1/en not_active Abandoned
- 2019-03-12 JP JP2019044553A patent/JP2019089850A/ja not_active Withdrawn
-
2020
- 2020-12-23 US US17/132,024 patent/US20210355191A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021032007A patent/JP2021080290A/ja active Pending
- 2021-07-07 IL IL284693A patent/IL284693A/en unknown
- 2021-08-05 US US17/395,365 patent/US20220204588A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284693A (en) | Actin-ACTRII antagonists and uses to increase red blood cell levels | |
HK1245147A1 (zh) | 激活素-actrii的拮抗劑及在提高紅細胞水平中的用途 | |
TWI561237B (en) | Substituted dihydropyrazolones and their use | |
EP2005504A4 (en) | ELECTROLYTE | |
AU313071S (en) | Battery | |
EP2070137A4 (en) | NEW SEPARATOR AND ELECTROCHEMICAL DEVICE COMPRISING SAME | |
HK1203089A1 (en) | Diagnosis and risk stratification using nt-proet-1 nt-proet-1 | |
GB0616045D0 (en) | Blood cell separation | |
HK1115238A1 (en) | Battery | |
EP2008335A4 (en) | IMPROVED ELECTROCHEMICAL DEVICE | |
EP2051313A4 (en) | BATTERY BUSH AND BATTERY THEREOF | |
EP2262038A4 (en) | Cell selector and cell with it | |
EP2043189A4 (en) | DRUMS | |
GB0616111D0 (en) | Agents, methods and uses | |
IL194899A0 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
EP2083461A4 (en) | BATTERY COVER AND BATTERY | |
EP1984728A4 (en) | MICRO-ELECTROCHEMICAL CELL AND METHODS OF INCORPORATING THE SAME | |
EP2262039A4 (en) | Cell selector and cell with it | |
HK1126128A1 (en) | Medicament for use in connection with cartilage impairment | |
GB0609926D0 (en) | Electrochemical cell | |
TWI369015B (en) | Battery structure | |
IL201346A0 (en) | Newcompositions and methods for cell killing | |
EP2048223A4 (en) | CELL CHIPS | |
HK1146065A1 (en) | Nlrr-1 antagonists and uses thereof nlrr-1 | |
GB0610059D0 (en) | Uses and methods |